Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidolin Plus
- Development stage
- Unknown
- Lead developer
- Orenda International
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidolin Plus is a combination herbal and probiotic dietary supplement developed by Orenda, primarily indicated for the restoration and maintenance of a healthy intestinal microbiome. The formulation contains the probiotic strain *Bifidobacterium animalis* subsp. *lactis* (often the BB-12 strain) and a root extract of *Inula helenium* (Elecampane). The probiotic component works by colonizing the gastrointestinal tract, competing with pathogenic microorganisms, and enhancing the intestinal barrier function. The *Inula helenium* extract provides a natural source of inulin, which acts as a prebiotic to stimulate the growth of beneficial bacteria, and contains sesquiterpene lactones that possess mild antimicrobial and anti-inflammatory properties. This product is typically used to manage dysbiosis, irritable bowel syndrome (IBS), and gastrointestinal disturbances associated with antibiotic use.
- Brand names
- Bifidolin Plus
02
Targets
TLR2 (Toll-like Receptor 2)NF-κB
Beyond the preview
Go deeper on Bifidolin Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidolin Plus.